Evolution of Acinetobacter baumannii infections and antimicrobial resistance. A review

Abstract The emergence of multi-drug resistant Acinetobacter spp involved in hospital-acquired infections, once considered an easily treatable pathogen, is troublesome and an immense burden for the modern medical systems worldwide. In the last 20 years the medical community recorded an increase in the incidence and severity of these infections as therapeutic means tend to be less and less effective on these strains. The ability of these bacteria to rapidly develop resistance to antimicrobial agents by continuously changing and adapting their mechanisms, their ability to survive for long periods of time in the hospital environment and the multitude of transmission possibilities raises serious issues regarding the management of these complex infections. The future lies in developing new and targeted methods for the early diagnosis of A. baumannii, as well as in the judicious use of antimicrobial drugs. This review details the evolution of the pathogenicity of this microorganism, together with the changes that appeared in resistance mechanisms and the advancements in molecular testing for the early detection of infection.

[1]  S. Réhman,et al.  Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities , 2018, Infection and drug resistance.

[2]  Qing Yang,et al.  Evolution of Acinetobacter baumannii In Vivo: International Clone II, More Resistance to Ceftazidime, Mutation in ptk , 2017, Front. Microbiol..

[3]  S. Castaldi,et al.  Risk factors and epidemiology of Acinetobacter baumannii infections in a university hospital in Northern Italy: A case-control study. , 2016, American journal of infection control.

[4]  B. Foxman,et al.  The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. , 2016, American journal of infection control.

[5]  M. Bacchi,et al.  Evaluation of molecular and biochemical methods to detect carbapenem-producing Acinetobacter baumannii , 2016 .

[6]  M. Pourhajibagher,et al.  Antimicrobial Resistance of Acinetobacter baumannii to Imipenem in Iran: A Systematic Review and Meta-Analysis , 2016, The open microbiology journal.

[7]  M. Adams,et al.  Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment , 2016, Genome Medicine.

[8]  N. Namias,et al.  Carbapenem-Resistant Acinetobacter baumannii: Concomitant Contamination of Air and Environmental Surfaces , 2016, Infection Control & Hospital Epidemiology.

[9]  R. Zarrilli.  Acinetobacter baumannii virulence determinants involved in biofilm growth and adherence to host epithelial cells , 2016, Virulence.

[10]  Cary L. Honnold,et al.  Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Peleg,et al.  Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options , 2015, Seminars in Respiratory and Critical Care Medicine.

[12]  C. Corbett,et al.  Development and characterization of monoclonal antibodies for rapid detection of Acinetobacter baumannii. , 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[13]  A. Sadiq,et al.  Isolation and Identification of Acinetobacter baumannii Clinical Isolates using Novel Methods , 2014 .

[14]  S. Molin,et al.  Genome Analysis of a Transmissible Lineage of Pseudomonas aeruginosa Reveals Pathoadaptive Mutations and Distinct Evolutionary Paths of Hypermutators , 2013, PLoS genetics.

[15]  Daniel J. Wilson,et al.  Insights from Genomics into Bacterial Pathogen Populations , 2012, PLoS pathogens.

[16]  H. Qiu,et al.  Role of Macrophages in Early Host Resistance to Respiratory Acinetobacter baumannii Infection , 2012, PloS one.

[17]  L. Morais,et al.  Pneumonia adquirida na comunidade numa criança saudável por Acinetobacter , 2012 .

[18]  L. Marques,et al.  Acinetobacter community-acquired pneumonia in a healthy child. , 2012, Revista portuguesa de pneumologia.

[19]  N. Woodford,et al.  Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System , 2011, Antimicrobial Agents and Chemotherapy.

[20]  Jian Li,et al.  Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production , 2010, Antimicrobial Agents and Chemotherapy.

[21]  P. Courvalin,et al.  Overexpression of Resistance-Nodulation-Cell Division Pump AdeFGH Confers Multidrug Resistance in Acinetobacter baumannii , 2010, Antimicrobial Agents and Chemotherapy.

[22]  S. H. Kim,et al.  Nosocomial Outbreak of Carbapenem-Resistant Acinetobacter baumannii in Intensive Care Units and Successful Outbreak Control Program , 2010, Journal of Korean medical science.

[23]  P. Nordmann,et al.  Overexpression of the Naturally Occurring blaOXA-51 Gene in Acinetobacter baumannii Mediated by Novel Insertion Sequence ISAba9 , 2009, Antimicrobial Agents and Chemotherapy.

[24]  J. Pachón,et al.  Nosocomial Outbreak of Infection With Pan–Drug-Resistant Acinetobacter baumannii in a Tertiary Care University Hospital , 2009, Infection Control & Hospital Epidemiology.

[25]  M. Vaneechoutte,et al.  Acinetobacter beijerinckii sp. nov. and Acinetobacter gyllenbergii sp. nov., haemolytic organisms isolated from humans. , 2009, International journal of systematic and evolutionary microbiology.

[26]  Carlene A. Muto,et al.  Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in Pennsylvania , 2008, Antimicrobial Agents and Chemotherapy.

[27]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[28]  G. B. Orsi,et al.  Multidrug-Resistant Acinetobacter baumannii Outbreak in an Intensive Care Unit , 2008, Journal of chemotherapy.

[29]  L. Dijkshoorn,et al.  Identification of widespread, closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  J. Desenclos,et al.  VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France. , 2006, Emerging infectious diseases.

[31]  S. Yoshizawa,et al.  Aminoglycoside resistance by ArmA-mediated ribosomal 16S methylation in human bacterial pathogens. , 2006, Journal of molecular biology.

[32]  P. Nordmann,et al.  Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  Jonathan R Edwards,et al.  Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  L. Dijkshoorn,et al.  Standardization and Interlaboratory Reproducibility Assessment of Pulsed-Field Gel Electrophoresis-Generated Fingerprints of Acinetobacter baumannii , 2005, Journal of Clinical Microbiology.

[35]  L. Rice,et al.  Identification of a New Allelic Variant of the Acinetobacter baumannii Cephalosporinase , ADC-7-Lactamase : Defining a Unique Family of Class C Enzymes ‡ , 2005 .

[36]  M. Wilcox,et al.  Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. , 2005, Intensive & critical care nursing.

[37]  M. Kaufmann,et al.  A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. , 2004, The Journal of hospital infection.

[38]  L. Dijkshoorn,et al.  Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. , 2004, Research in microbiology.

[39]  M. Vaneechoutte,et al.  Acinetobacter parvus sp. nov., a small-colony-forming species isolated from human clinical specimens. , 2003, International journal of systematic and evolutionary microbiology.

[40]  A. Balows.  Manual of clinical microbiology 8th edition , 2003, Diagnostic microbiology and infectious disease.

[41]  Robert J Seviour,et al.  Seven novel species of Acinetobacter isolated from activated sludge. , 2003, International journal of systematic and evolutionary microbiology.

[42]  M. Vaneechoutte,et al.  Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov., isolated from human clinical specimens. , 2001, International journal of systematic and evolutionary microbiology.

[43]  G. Bou,et al.  PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  H. Brade,et al.  Identification of Acinetobacter baumannii Strains with Monoclonal Antibodies against the O Antigens of Their Lipopolysaccharides , 1999, Clinical Diagnostic Laboratory Immunology.

[45]  O. Holst,et al.  Structural studies of the O-antigen isolated from the phenol-soluble lipopolysaccharide of Acinetobacter baumannii (DNA group 2) strain 9. , 1998, European journal of biochemistry.

[46]  O. Holst,et al.  Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter haemolyticus strain ATCC 17906. , 1997, European journal of biochemistry.

[47]  J Swings,et al.  Evaluation of the DNA fingerprinting method AFLP as an new tool in bacterial taxonomy. , 1996, Microbiology.

[48]  E Bergogne-Bérézin,et al.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features , 1996, Clinical microbiology reviews.

[49]  C. Urban,et al.  Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible acinetobacter baumannii , 1995 .

[50]  A Bueno-Cavanillas,et al.  Influence of nosocomial infection on mortality rate in an intensive care unit , 1994, Critical care medicine.

[51]  P. Rather,et al.  Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes , 1993 .

[52]  P. Gerner-Smidt,et al.  Reliability of phenotypic tests for identification of Acinetobacter species , 1991, Journal of clinical microbiology.

[53]  A. L. Rashad,et al.  Plasmid DNA fingerprinting of Acinetobacter calcoaceticus subspecies anitratus from intubated and mechanically ventilated patients. , 1990 .

[54]  J. Ursing,et al.  Clinical strains of Acinetobacter classified by DNA‐DNA hybridization , 1989, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[55]  J. Ware,et al.  Nitrosamine formation by clinical isolates of enteric bacteria , 1988 .

[56]  Patrick A. D. Grimont,et al.  Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii , 1986 .

[57]  B. Lugtenberg,et al.  Molecular architecture and functioning of the outer membrane of Escherichia coli and other gram-negative bacteria. , 1983, Biochimica et biophysica acta.